| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $79,287,865 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI188334 | Discovery of efflux pump inhibitors using a high-throughout bacterial assay | 001 | 2 | NIH | 12/29/2025 | $201,750 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL171056 | INTEGRATION OF MECHANICAL AND MOLECULAR CUES DURING DISTAL LUNG DEVELOPMENT | 000 | 3 | NIH | 3/6/2026 | $561,833 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P01AG062413 | Targeting Cellular Senescence to Extend Healthspan | 000 | 8 | NIH | 1/21/2026 | $3,158,891 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 000 | 4 | NIH | 12/22/2025 | $485,587 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30HD115297 | Role of Hofbauer cells in prenatal inflammation at the maternal-fetal interface | 000 | 2 | NIH | 12/24/2025 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32DK007198 | Multidisciplinary Training in Digestive Diseases | 002 | 51 | NIH | 4/9/2026 | $466,334 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AA030273 | Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines | 000 | 4 | NIH | 5/7/2026 | $375,271 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31NS141217 | Identifying molecular mechanisms contributing to disease etiology and the neurological symptoms associated with pediatric DPD deficiency | 002 | 2 | NIH | 3/31/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK142606 | A Randomized, placebo-controlled trial of the effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastrointestinal Functions and Relationship to Weight Loss | 000 | 2 | NIH | 4/9/2026 | $322,800 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS117944 | Acute Modulation of Stereotyped High Frequency Oscillations with a Closed-Loop Brain Interchange System in Drug Resistant Epilepsy | 000 | 4 | NIH | 5/1/2026 | $609,312 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK136731 | Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastography | 000 | 4 | NIH | 4/27/2026 | $399,749 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA305931 | Radiomic phenotypes for invasive and advanced breast cancer | 000 | 1 | NIH | 5/7/2026 | $722,914 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 000 | 4 | NIH | 5/5/2026 | $525,729 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB038746 | Overcoming Challenging Clinical Scenarios in Non-invasive Coronary Artery Imaging using Next Generation Photon Counting Detector CT and Artificial Intelligence | 001 | 1 | NIH | 4/6/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | RF1AG037491 | Understanding the role of TDP-43 in Alzheimer’s disease, FTLD and Related Disorders | 000 | 16 | NIH | 5/7/2026 | $3,391,515 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG097887 | Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on older adults | 000 | 1 | NIH | 3/13/2026 | $443,850 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33HL158811 | Pre-transplant health coaching to improve patient-reported outcomes in lung transplant candidates | 000 | 5 | NIH | 5/7/2026 | $492,749 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA307402 | Addressing Thyroid Cancer Overdiagnosis: AI-Driven Identification, Characterization, and Outcomes of Incidental Thyroid Nodules | 000 | 1 | NIH | 3/13/2026 | $676,067 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL084155 | Human Cardiorenal Syndrome | 000 | 14 | NIH | 4/28/2026 | $397,102 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 000 | 9 | NIH | 4/1/2026 | $643,670 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG086085 | Characterization of senescent cell populations in skeletal aging | 000 | 3 | NIH | 4/24/2026 | $520,831 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37AG011378 | Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers | 000 | 34 | NIH | 5/7/2026 | $785,776 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS132128 | Hybrid approach for comprehensive mutation detection in a cell | 000 | 4 | NIH | 4/2/2026 | $562,212 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076515 | Defining the interactions of senescent immune cells and skeletal cells | 000 | 5 | NIH | 3/20/2026 | $475,727 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB035553 | Improving the dose efficiency of photon counting CT | 000 | 3 | NIH | 4/13/2026 | $359,315 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG1CA232760 | Mayo Clinic Network Lead Academic Participating Site | 001 | 7 | NIH | 4/1/2026 | $1,043,247 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 000 | 8 | NIH | 4/24/2026 | $667,146 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG093767 | Premenopausal bilateral oophorectomy and biomarkers of Alzheimer’s and cerebrovascular diseases | 000 | 2 | NIH | 4/28/2026 | $1,702,288 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23HL164901 | Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle Training | 000 | 4 | NIH | 4/27/2026 | $167,741 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA301512 | Exploring LMTK2: A novel mediator of endocrine sensitivity in ER+ breast cancer | 001 | 1 | NIH | 4/9/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 001 | 1 | NIH | 3/31/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL161821 | Sorbs2 targeting and BK channel regulation in the coronary artery of patients with type 1 diabetes | 000 | 4 | NIH | 4/28/2026 | $674,656 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30HD115297 | Role of Hofbauer cells in prenatal inflammation at the maternal-fetal interface | 001 | 2 | NIH | 4/1/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK136511 | Pathobiology of liver fibrosis | 000 | 4 | NIH | 4/1/2026 | $355,080 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37AA021171 | Molecular Mechanisms of Liver Fibrosis | 000 | 15 | NIH | 4/24/2026 | $357,750 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285345 | Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer | 000 | 3 | NIH | 3/26/2026 | $492,046 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL146114 | Enhancing Respiratory Motor Function after Spinal Cord Injury | 000 | 8 | NIH | 3/25/2026 | $760,062 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R25DK101405 | Mayo Clinic Nephrology & Urology Summer Undergraduate Research Fellowship (nuSURF) | 000 | 13 | NIH | 3/24/2026 | $132,204 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160570 | Hydrogen Sulfide in Neonatal Airway Disease | 001 | 4 | NIH | 3/25/2026 | $17,892 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA288753 | Ovcoming PARP Inhibitor Resistance | 001 | 2 | NIH | 4/16/2026 | $63,372 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL107304 | Epicardial remodeling in cardiomyopathy and cardiac aging | 001 | 14 | NIH | 4/17/2026 | $18,911 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA273027 | Role of MALT1 in regulating the breast cancer immune microenvironment | 001 | 4 | NIH | 4/16/2026 | $54,368 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276005 | Aak1 to increase infiltration of adoptively transferred cells into solid tumors | 001 | 4 | NIH | 4/16/2026 | $45,762 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 002 | 5 | NIH | 4/16/2026 | $51,437 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA288862 | NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma | 001 | 2 | NIH | 4/17/2026 | $64,703 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA286864 | Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer | 000 | 3 | NIH | 4/17/2026 | $452,180 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285439 | Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC | 001 | 2 | NIH | 4/16/2026 | $46,346 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 001 | 4 | NIH | 4/16/2026 | $36,372 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 4 | NIH | 3/19/2026 | $671,520 |
|
